Albuvirtide plus 3BNC117 provides a promising combination strategy for multidrug-resistant HIV-1 infection: a prospective, open-label, multicenter phase 2 trial.

3BNC117 - Rockefeller University, Cornell University, Frontier Biotech, Gilead

Aikening (albuvirtide) - Frontier Biotech

http://www.ncbi.nlm.nih.gov/pubmed/41896772

Dong Xie; Kun He; Min Wang; Qingxia Zhao; Vijay Harypursat; Xia Liu; Xiaofeng Li; Yaokai Chen; Yihong Zhou; Ying Li; Yuanyuan Chen; Yuanyuan Qin

Mar 28, 2026